1. High level of αB-crystallin contributes to the progression of osteosarcoma
- Author
-
Yu-Rong Gu, Jun Luo, Ming Yin, Kai Wu, Qing-Ming Shi, and Xi-Gao Cheng
- Subjects
0301 basic medicine ,Adult ,Male ,Pathology ,medicine.medical_specialty ,Bone Neoplasms ,Matrix (biology) ,medicine.disease_cause ,Metastasis ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,In vivo ,Cell Line, Tumor ,medicine ,Biomarkers, Tumor ,Humans ,Secretion ,αB-Crystallin ,Extracellular Signal-Regulated MAP Kinases ,Osteosarcoma ,business.industry ,alpha-Crystallin B Chain ,medicine.disease ,invasion ,In vitro ,030104 developmental biology ,Cell Transformation, Neoplastic ,Oncology ,Matrix Metalloproteinase 9 ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,Disease Progression ,Female ,prognosis ,Neoplasm Recurrence, Local ,Carcinogenesis ,business ,MMP-9 ,Research Paper - Abstract
Accumulating evidences indicate the elevated expression of αB-Crystallin (Cryab) is implicated in tumorigenesis. However, the expression and biologic role of Cryab in osteosarcoma (OS) are still unknown. In this study, we showed that Cryab expression was elevated in OS tissues and cell lines, and down-regulation of Cryab in MG-63 and U-2OS cells led to a decline in the cells' aggressiveness, and reduced secretion of matrix metalloproteinase-9 (MMP-9) in vitro, and lower metastasis potential in vivo. Further study indicated that the Cryab expression was positively associated with the activity of ERK1/2 which is responsible for the cells' aggressiveness and MMP-9 secretion. Clinically, our data confirmed that the high level of Cryab was associated with shorten survival and tumor recurrence for the postoperative OS patients. Together, our results indicate that high level of Cryab is a new adverse outcomes marker for OS patients and may be used as a new therapeutic target.
- Published
- 2016